The geoepidemiology of Sjögren's syndrome

Autoimmunity Reviews

Volumn 9, Issue 5, 2010, Pages

  Mavragani, Clio P ^a   Moutsopoulos, Haralampos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clinical features; Differential diagnosis; Lymphoma; Pathogenesis; Sjogren's syndrome; Therapy

Indexed keywords

COMPLEMENT COMPONENT C4; CYTOKINE;

AUTOIMMUNE DISEASE; CANCER RISK; CLINICAL FEATURE; DYSPAREUNIA; ENVIRONMENTAL FACTOR; GEOGRAPHIC DISTRIBUTION; GLOMERULONEPHRITIS; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNE RESPONSE; INTERSTITIAL NEPHRITIS; LACRIMAL GLAND; LYMPHOCYTIC INFILTRATION; LYMPHOMA; PERIPHERAL NEUROPATHY; RAYNAUD PHENOMENON; REVIEW; SALIVARY GLAND; SEX RATIO; SJOEGREN SYNDROME; VASCULITIS; XEROSTOMIA;

AUTOIMMUNE DISEASES; FEMALE; HUMANS; LACRIMAL APPARATUS; MALE; SALIVARY GLAND DISEASES; SALIVARY GLANDS; SJOGREN'S SYNDROME; SYNDROME;

EID: 77649231925     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.11.004     Document Type: Review

References (40)

1. Kassan S.S., and Moutsopoulos H.M. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 164 12 (2004) 1275-1284
2. Novljan M.P., Rozman B., Jerse M., Rotar Z., Vidmar G., Kveder T., et al. Comparison of the different classification criteria sets for primary Sjögren's syndrome. Scand J Rheumatol 35 6 (Nov-Dec 2006) 463-467
3. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 6 (2002) 554-558
4. Mavragani C.P., Tzioufas A.G., and Moutsopoulos H.M. Sjögren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol 123 1 (Sep 2000) 46-57
5. Gabriel S.E., and Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11 3 (2009) 229
6. Hida A., Akahoshi M., Takagi Y., Ashizawa K., Imaizumi M., Soda M., et al. Prevalence of Sjogren syndrome among Nagasaki atomic bomb survivors. Ann Rheum Dis 67 5 (May 2008) 689-695
7. Haugen A.J., Peen E., Hultén B., Johannessen A.C., Brun J.G., Halse A.K., et al. Estimation of the prevalence of primary Sjögren's syndrome in two age-different community-based populations using two sets of classification criteria: the Hordaland Health Study. Scand J Rheumatol 37 1 (Jan-Feb 2008) 30-34
8. Mavragani C.P., Skopouli F.N., and Moutsopoulos H.M. Increased prevalence of antibodies to thyroid peroxidase in dry eyes and mouth syndrome or sicca asthenia polyalgia syndrome. J Rheumatol 36 8 (2009) 1626-1630
9. Katsifis G.E., Moutsopoulos N.M., and Wahl S.M. T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology. Clin Rev Allergy Immunol 32 3 (Jun 2007) 252-264
10. Manoussakis M.N., Boiu S., Korkolopoulou P., Kapsogeorgou E.K., Kavantzas N., Ziakas P., et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 56 12 (2007) 3977-3988 53
11. Triantafyllopoulou A., and Moutsopoulos H. Persistent viral infection in primary Sjogren's syndrome: review and perspectives. Clin Rev Allergy Immunol 32 3 (2007) 210-214
12. Bave U., Nordmark G., Lovgren T., Ronnelid J., Cajander S., Eloranta M.L., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 52 4 (2005) 1185-1195
13. Ittah M., Miceli-Richard C., Eric Gottenberg J., Lavie F., Lazure T., Ba N., et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 8 2 (2006) R51
14. Szodoray P., and Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 62 5 (2005) 421-428
15. Mitsias D.I., Tzioufas A.G., Veiopoulou C., Zintzaras E., Tassios I.K., Kogopoulou O., et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol 128 3 (2002) 562-568
16. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., and Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 175 3 (2009) 1167-1177
17. Espinosa A., Dardalhon V., Brauner S., Ambrosi A., Higgs R., Quintana F.J., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 206 8 (2009) 1661-1671
18. Sakai A., Sugawara Y., Kuroishi T., Sasano T., and Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 181 4 (2008) 2898-2906
19. Nguyen C.Q., Hu M.H., Li Y., Stewart C., and Peck A.B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum 58 3 (2008) 734-743
20. Turpie B., Yoshimura T., Gulati A., Rios J., Dartt D.A., and Masli S. Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol 175 3 (2009) 1136-1147
21. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos N.M., and Moutsopoulos H.M. Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 173 5 (2008) 1389-1396
22. Manoussakis M.N., and Kapsogeorgou E.K. The role of epithelial cells in the pathogenesis of Sjogren's syndrome. Clin Rev Allergy Immunol 32 3 (2007) 225-230
23. Skopouli F.N., and Moutsopoulos H.M. Autoimmune epitheliitis: Sjogren's syndrome. Clin Exp Rheumatol 12 Suppl 11 (1994) S9-S11
24. Scofield R.H. Genetics of systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 21 5 (2009) 448-453
25. Miceli-Richard C., Comets E., Loiseau P., Puechal X., Hachulla E., and Mariette X. Association of an IRF5 gene functional polymorphism with Sjogren's syndrome. Arthritis Rheum 56 12 (2007) 3989-3994
26. Miceli-Richard C., Gestermann N., Ittah M., Comets E., Loiseau P., Puechal X., et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjogren's syndrome. Arthritis Rheum 60 7 (2009) 1991-1997
27. Korman B.D., Alba M.I., Le J.M., Alevizos I., Smith J.A., Nikolov N.P., et al. Variant form of STAT4 is associated with primary Sjogren's syndrome. Genes Immun 9 3 (2008) 267-270
28. Nordmark G., Kristjansdottir G., Theander E., Eriksson P., Brun J.G., Wang C., et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome. Genes Immun 10 1 (2009) 68-76
29. Mamtani M., Anaya J.M., He W., and Ahuja S.K. Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases. Genes Immun (2009) [Sep 10, Electronic publication ahead of print]
30. Kirou K.A., Mavragani C.P., and Crow M.K. Activation of Type I interferon in systemic lupus erythematosus. Exp Rev Clin Immunol 3 (2007) 579-588
31. Karaiskos D., Mavragani C., Makaroni S., Zinzaras E., Voulgarelis M., Rabavilas A., et al. Stress, coping strategies and social support in patients with primary Sjogren's syndrome prior to disease onset: a retrospective case-control study. Ann Rheum Dis 68 1 (2009) 40-46 *equal contribution
32. Shim G.J., Warner M., Kim H.J., Andersson S., Liu L., Ekman J., et al. Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc Natl Acad Sci U S A 101 34 (2004) 12628-12633
33. Laine M., Porola P., Udby L., Kjeldsen L., Cowland J.B., Borregaard N., et al. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjogren's syndrome. Arthritis Rheum 56 8 (2007) 2575-2584
34. Mavragani C.P., Moutsopoulos N.M., and Moutsopoulos H.M. The management of Sjogren's syndrome. Nat Clin Pract Rheumatol 2 5 (2006) 252-261
35. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., Pillemer S.R., Wahl S.M., and Crow M.K. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 56 12 (2007) 3995-4004
36. Nakayamada S., Fujimoto T., Nonomura A., Saito K., Nakamura S., and Tanaka Y. Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy. Rheumatology (Oxford) 48 10 (2009 Oct) 1279-1282
37. Moutsopoulos H.M., and Fragoulis G.E. Is mizoribine a new therapeutic agent for Sjogren's syndrome?. Nat Clin Pract Rheumatol 4 7 (2008) 350-351
38. Rihl M., Ulbricht K., Schmidt R.E., and Witte T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome. Rheumatology (Oxford) 48 7 (2009) 796-799
39. Fukuda T., Shiraishi H., Nakamura T., Tanaka K., Nakamura H., Tsujino A., et al. Efficacy of tacrolimus in Sjogren's syndrome-associated CNS disease with aquaporin-4 autoantibodies. J Neurol 256 10 (2009 Oct) 1762-1764
40. Meijer J.M., Pijpe J., Vissink A., Kallenberg C.G., and Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 68 2 (2009) 284-285